Literature DB >> 23729401

Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.

Barbara Nuvoli1, Rossella Galati.   

Abstract

Malignant mesothelioma or mesothelioma is a rare form of cancer that develops from transformed cells originating in the mesothelium, the protective lining that covers many of the internal organs of the body. It is directly linked to asbestos exposure, which acts as a carcinogen by initiating the carcinogenic process. Because of their shape, asbestos fibers can cross the membrane barriers inside the body and cause inflammatory and fibrotic reactions. Such reactions are believed to be the mechanism by which asbestos fibers may trigger malignant mesothelioma in the pleural membrane around the lungs. Carcinogens are known to modulate the transcription factors, antiapoptotic proteins, proapoptotic proteins, protein kinases, cell-cycle proteins, cell adhesion molecules, COX-2, and growth factor signaling pathways. This article reviews recent studies regarding some malignant mesothelioma molecular targets not only for cancer prevention but also for cancer therapy. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23729401     DOI: 10.1158/1535-7163.MCT-12-1103

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  9 in total

1.  Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.

Authors:  Barbara Nuvoli; Barbara Antoniani; Roberta Libener; Antonio Maconi; Andrea Sacconi; Mariantonia Carosi; Rossella Galati
Journal:  J Exp Clin Cancer Res       Date:  2021-08-17

Review 2.  Reactive oxygen species a double-edged sword for mesothelioma.

Authors:  Serena Benedetti; Barbara Nuvoli; Simona Catalani; Rossella Galati
Journal:  Oncotarget       Date:  2015-07-10

3.  The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Authors:  Lily Oguh-Olayinka; Vijay Agarwal; Dulani Ranatunge; Anne Campbell; Stefan Laufer; Lynn Cawkwell; Michael J Lind
Journal:  Pathol Oncol Res       Date:  2019-04-02       Impact factor: 3.201

Review 4.  Curbing Lipids: Impacts ON Cancer and Viral Infection.

Authors:  Anika Dutta; Neelam Sharma-Walia
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

Review 5.  Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.

Authors:  Melanie Vogl; Anna Rosenmayr; Tomas Bohanes; Axel Scheed; Milos Brndiar; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

6.  Study on Mechanism of Jiawei Chaiqin Wendan Decoction in Treatment of Vestibular Migraine Based on Network Pharmacology and Molecular Docking Technology.

Authors:  Menglin Liu; Genhao Fan; Daopei Zhang; Mingjun Zhu; Huailiang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-31       Impact factor: 2.629

7.  Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma.

Authors:  Iacopo Gesmundo; Francesca Pedrolli; Nicoletta Vitale; Alessia Bertoldo; Giulia Orlando; Dana Banfi; Giuseppina Granato; Ramesh Kasarla; Federico Balzola; Silvia Deaglio; Renzhi Cai; Wei Sha; Mauro Papotti; Ezio Ghigo; Andrew V Schally; Riccarda Granata
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

8.  Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.

Authors:  Barbara Nuvoli; Sabrina Germoni; Carlotta Morosetti; Raffaela Santoro; Giancarlo Cortese; Serena Masi; Iole Cordone; Rossella Galati
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

9.  The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.

Authors:  Anuj Suri; Xiugui Sheng; Kevin M Schuler; Yan Zhong; Xiaoyun Han; Hannah M Jones; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2016-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.